Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has now recruited more than half the patients for its Phase IIa trial of its drug candidate QGC001. This is four months ahead of the recruitment schedule set by the company.
Olivier Madonna, Medical Director of Quantum Genomics, says :
“To date, over a third of the patients have fully completed the trial. The Supervisory Board – a group of independent experts tasked with reviewing the data from the trial – will meet within a month to examine the initial results. Its conclusions, especially concerning product tolerance in patients, will be released in the first half of October 2015.”
As a reminder, this clinical trial is conducted on some 30 patients with high blood pressure and the recrutement of first patients started early March 2015 (read the press release of 3 March 2015). The study involves four clinical investigation centres in France, under the supervision of Prof. Michel Azizi (Clinical Investigation Centre at Georges Pompidou European Hospital, Paris).
It is a randomised double-blind study, with cross-over, to compare the effects of the product QGC001 (500 mg morning and night) with those of a placebo. It also aims to analyse the pharmacodynamic effects of QGC001 on several hormonal biomarkers.
Quantum Genomics' goal is still to sign, by the end of 2016, a license agreement or partnership with a manufacturer in the healthcare sector to continue the clinical development of its product QGC001, its registration and commercialisation.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance & communication
+33 1 53 67 36 73
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, Inserm, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
Communiqués au titre de l'obligation d'information permanente :
- Activité de l'émetteur (acquisitions, cessions...)
Full and original press release in PDF:
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|QUANTUM GENOMICS||Euronext Paris||4.89 (c)||-2.20%||11 571|